The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802.
Ryota Saito
No relevant relationships to disclose
Akira Inoue
No relevant relationships to disclose
Shunichi Sugawara
No relevant relationships to disclose
Satoshi Oizumi
No relevant relationships to disclose
Makoto Maemondo
No relevant relationships to disclose
Koichi Okudera
No relevant relationships to disclose
Toshiro Suzuki
No relevant relationships to disclose
Kazuhiro Usui
No relevant relationships to disclose
Masao Harada
No relevant relationships to disclose
Naoto Morikawa
No relevant relationships to disclose
YUkihiro Hasegawa
No relevant relationships to disclose
Osamu Ishimoto
No relevant relationships to disclose
Tomohiro Sakakibara
No relevant relationships to disclose
Hajime Asahina
No relevant relationships to disclose
Toshihiro Nukiwa
No relevant relationships to disclose